Reshma Kewalramani
Reshma Kewalramani is a successful physician-scientist and pharmaceutical executive, currently serving as the CEO of Vertex Pharmaceuticals. Throughout her career, Kewalramani has made significant contributions to the field of medicine, both as a clinician and as a leader in the pharmaceutical industry. In this article, we will explore her early life, education, professional life, and achievements.
CEO’s | Actors | Politicians | Sports Stars
Early Life of Reshma Kewalramani
Reshma Kewalramani’s journey began in Bombay, India, where she was born and spent her childhood. The turning point in her life came when she and her family decided to move to the United States when she was 11 years old. This transcontinental shift marked the beginning of an inspirational journey that would see her break barriers and set new benchmarks in the biotechnology sector.
Personal Life
Living in Massachusetts, Reshma Kewalramani is a proud mother of twin sons, balancing her personal and professional lives with admirable grace. Her life outside the office, much like her professional journey, is a testament to her resilience, determination, and boundless energy.
Professional Life of Reshma Kewalramani
Reshma Kewalramani’s professional life is a remarkable blend of medicine and business, demonstrating her multifaceted skill set. After graduating from Boston University’s liberal arts/medical education program in 1998, Phi Beta Kappa, Summa Cum Laude, she completed her internship and residency at the Massachusetts General Hospital. She further honed her medical skills with a fellowship in nephrology at the Massachusetts General Hospital and Brigham and Women’s Hospital combined program.
Post her clinical nephrology fellowship, she engaged in transplantation research, and in 2015, she graduated from the General Management Program at Harvard Business School. This unique mix of medical and business education laid the foundation for her illustrious career in the biopharma sector.
Reshma Kewalramani started her professional journey as a physician at Massachusetts General Hospital and Brigham and Women’s Hospital. After gaining experience at the Massachusetts Eye and Ear Infirmary and the Massachusetts Institute of Technology, she made a successful transition into the biopharma sector. Here, she held key leadership positions at Amgen for over a decade.
In 2017, she joined Vertex Pharmaceuticals, and three years later, she assumed the role of president and CEO, becoming the first female CEO of a large US biotech company. Her leadership has led to the development of groundbreaking drugs like the cystic fibrosis therapy drug Trikafta and experimental apolipoprotein L1 inhibitor, VX-147. Under her guidance, Vertex has also collaborated with CRISPR Therapeutics to develop gene-editing therapies for sickle cell disease and beta thalassemia.
Awards and Recognitions
Reshma Kewalramani’s exceptional contributions to the medical and biopharma fields have not gone unnoticed. Over the years, she has received several awards and recognitions. Some of her notable achievements include the American College of Physicians Associates Council Award, the American Medical Women’s Association Janet M. Glasgow Memorial Achievement Citation, and the Harvard Medical School Excellence in Teaching Award.
In 2019, Reshma Kewalramani was bestowed with the TiE Boston Healthcare Leadership Award and was named one of Boston Business Journal’s Power 50. She made it to the inaugural Business Leaders List by Indiaspora, Business Insider’s list of 10 people transforming healthcare, and the PharmaVOICE 100 list of leaders in the life sciences in 2020. In 2021, she was the recipient of the International Institute of New England’s Golden Door Award and was named a New Englander of the Year by the New England Council. Under her leadership, Vertex Pharmaceuticals was ranked #2 on The Commonwealth Institute’s Top Women-Led Businesses in Massachusetts in 2021.
Age
As of the current year, Reshma Kewalramani’s exact age is not specified. However, considering she graduated from Boston University in 1998, she would likely be in her late 40s.
